EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review

Elise E Dunning, Boris Decourt, Nasser H Zawia, Holly A Shill, Marwan N Sabbagh

Neurology and Therapy · 2024-08 · 13 (4) · 975-1013

DOI: 10.1007/s40120-024-00614-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurology and Therapy, online erschienen am 14.05.2024. Verfasst von Elise E Dunning und 4 weiteren Autor:innen. Beteiligte Einrichtung: Creighton University School of Medicine - Phoenix, Phoenix, AZ, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 161 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau protein in specific areas of the midbrain, basal ganglia, and cortex. It is one of the most representative forms of tauopathy. PSP presents in several different phenotypic variations and is often accompanied by the development of concurrent neurodegenerative disorders. PSP is universally fatal, and effective disease-modifying therapies for PSP have not yet been identified. Several tau-targeting treatment modalities, including vaccines, monoclonal antibodies, and microtubule-stabilizing agents, have been investigated and have had no efficacy. The need to treat PSP and other tauopathies is critical, and many clinical trials investigating tau-targeted treatments are underway. In this review, the PubMed database was queried to collect information about preclinical and clinical research on PSP treatment. Additionally, the US National Library of Medicine's ClinicalTrials.gov website was queried to identify past and ongoing clinical trials relevant to PSP treatment. This narrative review summarizes our findings regarding these reports, which include potential disease-modifying drug trials, modifiable risk factor management, and symptom treatments.

Schlagwörter

Stichwörter der Autor:innen

Clinical trialsMicrotubule dysfunctionModifiable risk factorMonoclonal antibodyProgressive supranuclear palsyTauTau phosphorylation

Autor:innen und Institutionen

  • Creighton University School of Medicine - Phoenix, Phoenix, AZ, USA.
  • Department of Pharmacology and Neuroscience School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Laboratory on Neurodegeneration and Translational Research, College of Medicine, Roseman University of Health Sciences, Las Vegas, NV, USA.
  • Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar.
  • Department of Biomedical and Pharmaceutical Sciences, Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA.
  • Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W Thomas Rd, Phoenix, AZ, 85013, USA.

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Institutes of Health
  • Barrow Neurological Foundation

Zitieren

APA

Dunning, E. E., Decourt, B., Zawia, N. H., Shill, H. A., & Sabbagh, M. N. (2024). Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review. Neurology and Therapy, 13(4), 975-1013. https://doi.org/10.1007/s40120-024-00614-9

Vancouver

Dunning EE, Decourt B, Zawia NH, Shill HA, Sabbagh MN. Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review. Neurology and Therapy. 2024;13(4):975-1013. doi:10.1007/s40120-024-00614-9

BibTeX
@article{Dunning2024,
  author = {Dunning, Elise E and Decourt, Boris and Zawia, Nasser H and Shill, Holly A and Sabbagh, Marwan N},
  title = {Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review},
  journal = {Neurology and Therapy},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {975--1013},
  doi = {10.1007/s40120-024-00614-9}
}
Kostenlos starten →